From Medscape Neurology

Coverage from the

35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019

September 11 - 13, 2019; Stockholm, Sweden

September 11 - 13, 2019 Stockholm, Sweden
  • Anti-CD19 MAb Trial Halted Early for Benefit in NMO Inebilizumab is one of three new treatments for neuromyelitis optica — which have all shown striking degrees of efficacy — but are likely to be much more expensive than current mainstay therapy.
  • Antibody Monotherapy Shows Promise in Neuromyelitis Optica Satralizumab as monotherapy is effective vs placebo for reducing risk of relapses in patients with autoimmune neuromyelitis optica spectrum disorder (NMOSD), new research suggests.
  • ECTRIMS 2019 MESEMS: No Reduction in MS Lesions With Stem Cell Therapy Although the primary outcome of a multinational phase 2 study was negative, researchers said promising secondary findings support the use of mesenchymal stem cells in patients with MS.

Conference News

Popular News from ECTRIMS 2018

Medscape Neurology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.